Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009.
Int J Tuberc Lung Dis
; 16(6): 812-6, 2012 Jun.
Article
in En
| MEDLINE
| ID: mdl-22507372
ABSTRACT
BACKGROUND:
The optimal management strategy for patients with isoniazid (INH) monoresistant forms of tuberculosis (TB) has been widely debated. The current daily 9-month regimen of rifampin, pyrazinamide and ethambutol was established based largely on trials in settings with low TB rates and low rates of drug resistance.OBJECTIVE:
To explore the outcomes of patients with INH-monoresistant TB in the country of Georgia, a setting with both high TB rates and drug-resistant forms of the disease.METHODS:
Retrospective record review of all patients diagnosed with smear-positive pulmonary TB resistant to either INH or INH+SM (streptomycin) in Georgia between 2007 and 2009.RESULTS:
Of 8752 patients with pulmonary TB registered in Georgia, 909 were found to have INH or INH+SM resistance. Treatment outcomes were relatively poor in this group, with only 71% treatment success. Outcomes were significantly worse among patients with older age and a history of previous treatment.CONCLUSIONS:
INH or INH+SM resistance in pulmonary TB patients in Georgia is common. The low rates of treatment success suggest the need for an improved treatment regimen for patients with resistance to these first-line drugs; this need is particularly pronounced among the subset of patients with a history of previous treatment.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pyrazinamide
/
Rifampin
/
Tuberculosis
/
Drug Resistance, Bacterial
/
Ethambutol
/
Isoniazid
/
Mycobacterium tuberculosis
/
Antitubercular Agents
Type of study:
Diagnostic_studies
/
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Europa
Language:
En
Journal:
Int J Tuberc Lung Dis
Year:
2012
Document type:
Article
Affiliation country:
Georgia